Metabolic factors and post-traumatic arthritis may influence the increased rate of surgical site infection in patients with human immunodeficiency virus following total hip arthroplasty.
Highly active antiretroviral therapy (HAART)
Human immunodeficiency virus (HIV)
Surgical site infection (SSI)
Total hip arthroplasty
Journal
Journal of orthopaedic surgery and research
ISSN: 1749-799X
Titre abrégé: J Orthop Surg Res
Pays: England
ID NLM: 101265112
Informations de publication
Date de publication:
12 Aug 2020
12 Aug 2020
Historique:
received:
05
12
2019
accepted:
29
07
2020
entrez:
14
8
2020
pubmed:
14
8
2020
medline:
29
4
2021
Statut:
epublish
Résumé
The impact of CD4+ T-cell count and highly active antiretroviral therapy (HAART) on the rate of surgical site infection (SSI) in patients with human immunodeficiency virus (HIV) undergoing total hip arthroplasty is still unclear. The goals of this study were to assess the rate of perioperative infection at a large tertiary care referral center and to identify risk factors in HIV+ patients undergoing total hip arthroplasty (THA). This study was a prospective, observational study at a single medical center from 2000-2017. Patients who were HIV+ and underwent THA were followed from the preoperative assessment period, through surgery and for a 2-year follow-up period. Sixteen of 144 HIV+ patients (11%) undergoing THA developed perioperative surgical site infections. Fourteen patients (10%) required revision THA within a range of 12 to 97 days after the initial surgery. The patients' mean age was 49.6 ± 4.5 years, and the most common diagnosis prompting THA was osteonecrosis (96%). Patients who developed SSI had a lower waist-hip ratio (0.86 vs. 0.93, p = 0.047), lower high density lipoprotein cholesterol (45.8 vs. 52.5, p = 0.015) and were more likely to have post-traumatic arthritis (12.5% vs. 0%, p = 0.008). Logistic regression analysis demonstrated that current alcohol use and higher waist-hip ratio were significant protectors against infection (p < 0.05). No other demographic, medical, immunologic parameters, or specific HAART regimens were associated with perioperative infection. Immunologic status as measured by CD4+ cell count, HIV viral load, and medical therapy do not appear to influence the development of SSI in HIV+ patients undergoing THA. Metabolic factors and post-traumatic arthritis may influence the increased rate of infection in HIV+ patients following THA.
Sections du résumé
BACKGROUND
BACKGROUND
The impact of CD4+ T-cell count and highly active antiretroviral therapy (HAART) on the rate of surgical site infection (SSI) in patients with human immunodeficiency virus (HIV) undergoing total hip arthroplasty is still unclear. The goals of this study were to assess the rate of perioperative infection at a large tertiary care referral center and to identify risk factors in HIV+ patients undergoing total hip arthroplasty (THA).
METHODS
METHODS
This study was a prospective, observational study at a single medical center from 2000-2017. Patients who were HIV+ and underwent THA were followed from the preoperative assessment period, through surgery and for a 2-year follow-up period.
RESULTS
RESULTS
Sixteen of 144 HIV+ patients (11%) undergoing THA developed perioperative surgical site infections. Fourteen patients (10%) required revision THA within a range of 12 to 97 days after the initial surgery. The patients' mean age was 49.6 ± 4.5 years, and the most common diagnosis prompting THA was osteonecrosis (96%). Patients who developed SSI had a lower waist-hip ratio (0.86 vs. 0.93, p = 0.047), lower high density lipoprotein cholesterol (45.8 vs. 52.5, p = 0.015) and were more likely to have post-traumatic arthritis (12.5% vs. 0%, p = 0.008). Logistic regression analysis demonstrated that current alcohol use and higher waist-hip ratio were significant protectors against infection (p < 0.05). No other demographic, medical, immunologic parameters, or specific HAART regimens were associated with perioperative infection.
CONCLUSIONS
CONCLUSIONS
Immunologic status as measured by CD4+ cell count, HIV viral load, and medical therapy do not appear to influence the development of SSI in HIV+ patients undergoing THA. Metabolic factors and post-traumatic arthritis may influence the increased rate of infection in HIV+ patients following THA.
Identifiants
pubmed: 32787972
doi: 10.1186/s13018-020-01827-y
pii: 10.1186/s13018-020-01827-y
pmc: PMC7425402
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
316Références
Arch Surg. 2006 Dec;141(12):1238-45
pubmed: 17178967
Lancet. 1998 Jun 20;351(9119):1881-3
pubmed: 9652687
AIDS. 1998 Dec 3;12(17):2243-51
pubmed: 9863865
Injury. 2009 Nov;40(11):1147-50
pubmed: 19467653
BMC Infect Dis. 2015 Jul 17;15:274
pubmed: 26183704
HIV Med. 2012 Nov;13(10):623-9
pubmed: 22500743
J Bone Joint Surg Am. 2013 Oct 16;95(20):1845-50
pubmed: 24132358
Int Orthop. 2012 Jun;36(6):1155-61
pubmed: 22207406
J Lipid Res. 2014 Feb;55(2):168-79
pubmed: 23812558
J Arthroplasty. 2018 Jul;33(7S):S86-S92.e1
pubmed: 29198873
J Bone Joint Surg Am. 1996 Apr;78(4):512-23
pubmed: 8609130
J Clin Neurosci. 2015 Dec;22(12):1862-6
pubmed: 26282155
J Arthroplasty. 2016 Oct;31(10):2146-51
pubmed: 27131415
Am J Cardiol. 2001 Dec 1;88(11):1264-9
pubmed: 11728354
Acta Cardiol. 2008 Feb;63(1):65-72
pubmed: 18372583
Mayo Clin Proc. 2014 Mar;89(3):382-93
pubmed: 24582196
J Arthroplasty. 2013 Sep;28(8):1254-8
pubmed: 23523495
Prog Cardiovasc Dis. 2018 May - Jun;61(1):68-75
pubmed: 29458056
J Am Coll Cardiol. 2008 Aug 12;52(7):569-76
pubmed: 18687253
Eur J Surg. 1998 Jul;164(7):483-7
pubmed: 9696968
JBJS Rev. 2018 May;6(5):e10
pubmed: 29847443
Am J Med. 2005 Apr;118 Suppl 2:23S-28S
pubmed: 15903292
J Bone Joint Surg Am. 2005 Aug;87(8):1712-8
pubmed: 16085609
Clin Orthop Relat Res. 2013 Oct;471(10):3112-9
pubmed: 23519927
Am J Surg. 2000 Sep;180(3):228-33
pubmed: 11084136
J Bone Joint Surg Am. 2009 Jul;91(7):1621-9
pubmed: 19571084
J Arthroplasty. 2014 Feb;29(2):277-82
pubmed: 23867663
J Am Acad Orthop Surg. 2002 Sep-Oct;10(5):312-20
pubmed: 12374482
J Arthroplasty. 1995 Aug;10(4):448-52
pubmed: 8523002
AIDS. 1999 Jul 30;13(11):1287-93
pubmed: 10449280
Int Wound J. 2017 Jun;14(3):529-536
pubmed: 27397553
PLoS One. 2016 Mar 03;11(3):e0150866
pubmed: 26938768
J Trauma. 1994 Oct;37(4):545-50; discussion 550-1
pubmed: 7932883
Diabetologia. 2004 Oct;47(10):1760-7
pubmed: 15502925
Clin Orthop Relat Res. 2009 Jul;467(7):1670-3
pubmed: 19225851
Clin Orthop Relat Res. 2012 May;470(5):1507-12
pubmed: 22207561
Ann Intern Med. 2007 Jan 16;146(2):87-95
pubmed: 17227932
JAMA Surg. 2015 Apr;150(4):343-51
pubmed: 25714794
JAMA. 1992 Apr 1;267(13):1798-805
pubmed: 1347573
J Am Acad Orthop Surg. 1996 Nov;4(6):297-304
pubmed: 10797197
Lancet. 1999 Jun 19;353(9170):2093-9
pubmed: 10382692
Orthopedics. 2014 Apr;37(4):257-65
pubmed: 24762833
J Bone Joint Surg Am. 2012 Jul 18;94(14):e101
pubmed: 22810408
Lancet. 2008 Jul 26;372(9635):293-9
pubmed: 18657708
J Arthroplasty. 2001 Apr;16(3):330-5
pubmed: 11307131
J Arthroplasty. 2015 Sep;30(9):1629-32
pubmed: 25891433
Curr Opin HIV AIDS. 2009 May;4(3):176-82
pubmed: 19532047
J Bone Joint Surg Br. 2001 Sep;83(7):1050-4
pubmed: 11603522
J Acquir Immune Defic Syndr. 2006 Sep;43(1):27-34
pubmed: 16878047
Curr Opin Lipidol. 2004 Jun;15(3):269-78
pubmed: 15166782
J Bone Joint Surg Am. 2013 Jun 5;95(11):1028-36
pubmed: 23780541
Clin Dev Immunol. 2012;2012:670957
pubmed: 22474480